aTyr Pharma ATYR Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

CytomX TherapeuticsCTMX

——

Rigel PharmaceuticalsRIGL

——

ZymeworksZYME

——

Spyre Therapeutics, Inc.SYRE

——

Other financials

Income statement

See full

Revenue-—

Operating income-$11.4M+27.5%

Net income-$10.8M+27.5%

EPS (diluted)-$0.11+35.3%

Balance sheet

See full

Cash & equivalents$10.0M-3.4%

Total debt$12.3M-9.2%

Total equity$57.9M-22.8%

Total assets$79.7M-18.1%

Cash flow

See full

Operating cash flow-$12.5M+18.8%

CapEx$138.0K—

Free cash flow-$12.7M+17.9%

Valuation

See full

Market cap$54.88M-88.2%

Enterprise value$57.17M—

P/S288.8×—

Profitability

See full

Operating margin-40,856.3%+28,833pp

Net margin-39,009.5%+29,653pp

FCF margin-32,664.7%+4,018pp

Returns & leverage

See full

Return on equity-105.3%+50.6pp

Debt / equity0.2×0.0×

Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is aTyr Pharma's proceeds from exercises of stock options and other stock issuances?: aTyr Pharma (ATYR) reported proceeds from exercises of stock options and other stock issuances of $0 in Q1 2026.
How has aTyr Pharma's proceeds from exercises of stock options and other stock issuances changed year-over-year?: aTyr Pharma's proceeds from exercises of stock options and other stock issuances decreased by 100.0% year-over-year, from $2K to $0.